Abstract Details

Title Migraine and Functional Impairment Associated with Driving: Results of the OVERCOME Study

Topic Headache

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 7-009

Objective

Characterize driving behaviors in people with migraine from the ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) study.

Background

Migraine is associated with substantial functional burden, yet little is known about migraine-related driving impairment.

Design/Methods

OVERCOME is a web-based survey conducted in a representative US sample. The sample collected in Spring 2019 assessed the impact of migraine on driving frequency, duration of driving avoidance during headache, and days with an inability to drive. Monthly headache days (MHDs), MIDAS score, headache pain, and attack-related disability were assessed. Differences between categorical variables were assessed with Chi-square statistics and correlations were assessed with Spearman’s rho (r).

Results

Among 5485 eligible participants with migraine and valid driver’s licenses, mean (SD) age was 49.7 (14.2) and mean MHDs was 5.9 (7.0); 13.2% had chronic migraine. Mean MIDAS score was 14.3 (26.1); 19.5% had severe MIDAS disability. As pain intensity increased, the proportion reporting not driving with headache increased from mild (27.1%) to moderate (38.4%) to severe (66.0%) pain (p<0.0001 vs mild for both). Duration of driving avoidance increased with increasing MIDAS grade (r= 0.39), attack-related disability (r=0.39), and MHDs (r=0.18; p<0.0001 for all). The proportion of patients with ≥7 hours of driving avoidance increased with disability from moderate (26.6%) to severe (37.1%) to very severe (52.1%) (p<0.001). Among patients whose working ability was severely impaired or who required bed rest, 25.4% and 42.9% reported ≥7 hours of driving avoidance during attacks. Days with inability to drive in the past 90 days increased as migraine-related disability and MHDs increased (p<0.001).

Conclusions

An increasing proportion of people with migraine avoid driving as pain intensity increases, reaching 66% for those with severe pain. Driving avoidance lasting ≥7 hours occurs in almost half of those with severe disability. The impact of migraine on driving merits additional attention and clinical assessment.

Authors/Disclosures
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) PRESENTER	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Li Shen Loo	No disclosure on file
	No disclosure on file
Robert A. Nicholson, PhD (Eli Lilly & Company)	Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
Erin G. Doty, MD (Eli Lilly and Company)	Dr. Doty has received personal compensation for serving as an employee of Eli Lilly and Company, USA. Dr. Doty has stock in Eli Lilly and Company, USA.
Hu Li	No disclosure on file
Dawn C. Buse, PhD (Dawn C. Buse, PhD)	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Robert E. Shapiro, MD, PhD, FAAN (Larner College of Medicine, University of Vermont)	Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Shapiro has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for EEOC.
Michael L. Reed, PhD (Vedanta Research)	The institution of Dr. Reed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Reed has received research support from Allergan. The institution of Dr. Reed has received research support from Dr Reddy's Labs/Promius. The institution of Dr. Reed has received research support from Allay Lamp. Dr. Reed has a non-compensated relationship as a Research Analyst with National Headache Foundation that is relevant to AAN interests or activities.
Eric Pearlman, MD	Dr. Pearlman has received personal compensation for serving as an employee of Eli Lilly and Co. Dr. Pearlman has received stock or an ownership interest from Eli Lilly and Co.

��ɫ��

��ɫ��